Randox boosts its sales drive in America
Northern Ireland pharma giant Randox is continuing to ramp up its business in the US, following the UK's decision to leave the EU.
The Crumlin firm is travelling to the American Association of Clinical Chemistry's annual meeting in Philadelphia to take part in the world's largest diagnostics conference.
Dr Peter FitzGerald, founder of Randox, said: "The USA is one of our most important markets and we have been exporting our diagnostic products there since the early 1980s.
"For example, we have Randox Clinical Chemistry Analysers in key Ivy League Institutions, such as Yale University School of Medicine and Harvard University.
"It is vital to nurture and develop these key relationships, as well as endeavour to establish new ones."
Randox's expertise in diagnostics means that the company has been able to diversify beyond healthcare, into the veterinary, research, forensic and food safety sectors in North America.
Earlier this month, Dr Fitzgerald said he does not believe Brexit will damage his company, as he announced it has surpassed £1bn in sales of medical tests.
Dr FitzGerald said he is optimistic about the future of the Co Antrim company, despite the ongoing economic uncertainty related to the UK leaving the EU.
And he also welcomed any reduction in corporation tax as good for business.